Navigation Links
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
Date:7/26/2010

or only six to 10 months.(i) The single-agent activity with durable disease control and favorable tolerability observed in this study indicate that carfilzomib has the potential to alter the natural course of this deadly disease."

"Carfilzomib has the potential to be an important therapy in multiple myeloma and exemplifies the Onyx vision to build a leading oncology company by developing innovative targeted therapies," said N. Anthony Coles, M.D., President and Chief Executive Officer of Onyx Pharmaceuticals. "We are committed to bringing this promising treatment to patients as quickly as possible by pursuing an accelerated approval pathway in the U.S., while simultaneously moving forward with two Phase 3 studies. The first study, ASPIRE, is designed to support full carfilzomib registration in the U.S. in earlier-stage patients who have relapsed following initial lines of therapy, and the second study is designed to support approval in relapsed and refractory patients in Europe."

Trial Design

The 003-A1 study was an open-label, single-arm Phase 2b trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma whose disease was refractory to their last treatment regimen and who had received at least two prior therapies, including bortezomib, either thalidomide or lenalidomide, an alkylating agent, glucocorticoids and an anthracycline. Refractory disease was defined as < 25% response or progression during therapy or within 60 days after completion of therapy.(ii) Patients enrolled in the 003-A1 trial had received a median of five prior therapeutic regimens, corresponding to a median of 13 anti-myeloma agents. Patients received carfilzomib at 20mg/m2 for the first cycle followed by 27mg/m2 thereafter for up to 12 cycles. Patients who completed the 12 cyc
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
2. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
5. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
6. Lotus Pharmaceuticals Terminates SEDA
7. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
8. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
9. Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010
10. Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector
11. Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)...  According to the American Optometric Association (AOA), parents ... devices. An AOA survey reports that 83 percent of ... they use an electronic device for three or more ... parents revealed that only 40 percent of parents believe ... amount of time. Eye doctors are concerned that this ...
(Date:7/22/2014)... MARCOS, Texas , July 22, 2014 Quantum Materials ... and Mr. John Heaton to the Board of ... by Dr. Ghassan Jabbour , QMC Chief Science Officer and ... Michael Wong of Rice University and Mr. Tomio ... Japan . " Quantum Materials welcomes ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Pharmaceuticals, Inc. announced today that the U.S. Food ... drug status for the treatment of pancreatic cancer. ... the marketed chemotherapy drug irinotecan.  MM-398 is partnered ... Taiwan under the designation PEP02. (Logo: ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced ... the NASDAQ Global Select Market closes on Tuesday, August 9, ... Executive Officer, will host a conference call and webcast at ... the financial results for the second quarter 2011 and to ...
Cached Medicine Technology:FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 3
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) ... owing to novel medical indications created and due to ... societies where physical appearance is extremely valued. Although the ... competitors, new companies and technologies are setting ground for ... put the price of 1st-gen products under pressure, only ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, ... invasive procedure known as morcellation carries a risk of spreading ... more clearly. Twenty-seven of every 10,000 women who had ... the procedure, researchers found, with the odds being highest for ... hysterectomy with morcellation use a power cutter to slice uterine ...
(Date:7/22/2014)... French . Montreal, ... step out for a cigarette twice as often as smokers ... who have the hardest time shaking off the habit may ... of. , Those insights were among the collective findings recently ... by a team of researchers based in part at Concordia ...
(Date:7/22/2014)... 22, 2014 5i Sciences, a medical ... appointment of Molly Coye, M.D., M.P.H. to a role ... renowned authority on the market introduction of innovative technologies ... she will advise on strategies for building a successful ... technology. Dr. Coye is currently the Chief Innovation ...
(Date:7/22/2014)... 2014 The Latin America Drilling fluid and ... and completion fluid market in Latin America with analysis and ... in Latin America is estimated to grow from around $0.93 ... CAGR of 9.2%, for the given period. , Browse through ... fluid Market Report, to get an idea of the in-depth ...
Breaking Medicine News(10 mins):Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:Extra exercise helps depressed smokers kick the habit faster 2Health News:5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 6
... Announces 2008,Journalistic Achievement Awards, NEW YORK, May ... Show are among winners receiving top honors,in the ... for Aesthetic Plastic Surgery (ASAPS). Selected from among ... their awards on May,6th, at ASAPS, Annual Meeting ...
... $12.5 million private placement, SHANGHAI, China, May ... or "ATG") (OTC Bulletin Board: AAXT),today announced that, ... of all the outstanding common stock of Asian ... ("ABM"),pursuant to a share exchange agreement. ATG acquired ...
... Many women under age 55 arent seeking timely treatment for ... reaction to follow a Hollywood script tightening in the ... one knee. , Thats the finding of researchers who presented ... on Quality of Care and Outcomes Research (QCOR) in Cardiovascular ...
... Finding could help men with precancerous lesions avoid unnecessary ... Spanish researchers report they may have found a way ... develop into cancer. , The findings, published in the ... show a link between high-grade prostatic intraepithelial neoplasia (HG-PIN) ...
... Wound Closure System earns high marks from ... combat surgeons, ... U.S. Army combat support surgeons in Baghdad show that a new,medical device ... and limbs of soldiers and civilians., A team of battle zone ...
... the Decade Announced at Special 10th Anniversary ... Ceremony in Washington, DC -, ... honor six inspiring winners at the 10th annual Welcome Back Awards,ceremony ... the,Welcome Back Awards has recognized individuals for their outstanding,commitments to mental ...
Cached Medicine News:Health News:Aesthetic Society Awards Journalists' Commitment to Patient Education 2Health News:Aesthetic Society Awards Journalists' Commitment to Patient Education 3Health News:Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc. 2Health News:Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc. 3Health News:Shanghai Medical Technology Co., Ltd. Completes Merger With Aamaxan Transport Group, Inc. 4Health News:Some women more likely to miss or ignore heart attack warning signs 2Health News:Some women more likely to miss or ignore heart attack warning signs 3Health News:Biomarker Spots Which Lesions Likely to Progress to Prostate Cancer 2Health News:New Surgical Device Saves Lives and Limbs on Iraq's Front Lines 2Health News:New Surgical Device Saves Lives and Limbs on Iraq's Front Lines 3Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 2Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 3Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 4Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 5Health News:2008 Welcome Back Awards Winners Honored for Extraordinary Achievements in the Field of Depression 6
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... kit measures the biologically active form ... is a valuable prognostic marker for cardiovascular ... plasma vitamin B6 level and Coronary Heart ... reactions of homocysteine to cystathionine and then ...
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: